Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor (FGFR)1-4 inhibitor with potent preclinical activity against tumors harboring FGFR aberrations. This first-in-human, phase I dose-escalation trial (NCT02052778) evaluates the safety and pharmacokinetics/pharmacodynamics of futibatinib in advanced solid tumors. PATIENTS AND METHODS: Following a standard 3+3 dose-escalation design, eligible patients with advanced solid tumors refractory to standard therapies received 8-200 mg futibatinib three times a week (t.i.w.) or 4-24 mg once daily (q.d.). RESULTS: A total of 86 patients were enrolled in the nine t.i.w. (n = 42) and five q.d. cohorts (n = 44); 71 patients (83%) had tumors harboring FGF/FGFR aberrations. Three of nine patients in the 24-mg q.d. cohort experienced dose-limiting toxicities, including grade 3 increases in alanine transaminase, aspartate transaminase, and blood bilirubin (n = 1 each). The maximum tolerated dose (MTD) was determined to be 20 mg q.d.; no MTD was defined for the t.i.w. schedule. Across cohorts (n = 86), the most common treatment-emergent adverse events (TEAEs) were hyperphosphatemia (59%), diarrhea (37%), and constipation (34%); 48% experienced grade 3 TEAEs. TEAEs led to dose interruptions, dose reductions, and treatment discontinuations in 55%, 14%, and 3% of patients, respectively. Pharmacokinetics were dose proportional across all q.d. doses but not all t.i.w. doses evaluated, with saturation observed between 80 and 200 mg t.i.w. Serum phosphorus increased dose dependently with futibatinib on both schedules, but a stronger exposure-response relationship was observed with q.d. dosing, supporting 20 mg q.d. as the recommended phase II dose (RP2D). Overall, partial responses were observed in five patients [FGFR2 fusion-positive intrahepatic cholangiocarcinoma (n = 3) and FGFR1-mutant primary brain tumor (n = 2)], and stable disease in 41 (48%). CONCLUSIONS: Futibatinib treatment resulted in manageable safety, pharmacodynamic activity, and preliminary responses in patients with advanced solid tumors. The results of this phase I dose-escalation trial support 20 mg q.d. futibatinib as the RP2D. CLINICAL TRIAL REGISTRATION: FOENIX-101 (ClinicalTrials.gov, NCT02052778).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611 · cited 1×
“5) Sex, n (%) Male 19 (45) 15 (34) 34 (40) Female 23 (55) 29 (66) 52 (60) Race, n (%) White 31 (74) 28 (64) 59 (69) Black 1 (2) 1 (2) 2 (2) Asian 0 (0) 3 (7) 3 (3) Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) ≥1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Chola…”
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808 · cited 2×
“Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) 1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Cholangiocarcinoma 7 (17) 17 (39) 24 (28) Intrahepatic 6 (14) 16 (36) 22 (26) Extrahepatic 1 (2) 1 (2) 2 (2) Breast 7 (17) 5 (11) 12 (14) Colorectal 7 (17) 5 (11) 12 (14)…”
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5009 · Cited by 693 · cited 2×
“Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) 1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Cholangiocarcinoma 7 (17) 17 (39) 24 (28) Intrahepatic 6 (14) 16 (36) 22 (26) Extrahepatic 1 (2) 1 (2) 2 (2) Breast 7 (17) 5 (11) 12 (14) Colorectal 7 (17) 5 (11) 12 (14)…”
Self-citationArai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553 · cited 2×
“Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) 1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Cholangiocarcinoma 7 (17) 17 (39) 24 (28) Intrahepatic 6 (14) 16 (36) 22 (26) Extrahepatic 1 (2) 1 (2) 2 (2) Breast 7 (17) 5 (11) 12 (14) Colorectal 7 (17) 5 (11) 12 (14)…”
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552 · cited 1×
“Any TEAE 42 (100) 3 (7) 14 (33) 20 (48) 2 (5) 44 (100) 5 (11) 11 (25) 21 (48) 3 (7) Any treatment-related AE 37 (88) 12 (29) 14 (33) 10 (24) 1 (2) 41 (93) 13 (30) 11 (25) 16 (36) 1 (2) Action taken because of TEAE Dosing delay/interruption 21 (50) 0 (0) 6 (14) 14 (33) 1 (2) 26 (59) 1 (2) 9 (20) 16 (36) 0 (0) Dose redu…”
Self-citationMazzaferro, V., El-Rayes, B. F., Droz dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0334-0 · Cited by 365
Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
Haugsten, E. M., Wiedlocha, A., Olsnes, S., & Wesche, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0168 · Cited by 315
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 157 · cited 1×
“Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) 1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Cholangiocarcinoma 7 (17) 17 (39) 24 (28) Intrahepatic 6 (14) 16 (36) 22 (26) Extrahepatic 1 (2) 1 (2) 2 (2) Breast 7 (17) 5 (11) 12 (14) Colorectal 7 (17) 5 (11) 12 (14)…”
Wöhrle, S., Bonny, O., Beluch, N., Gaulis, S., Stamm, C., Scheibler, M., Müller, M., Kinzel, B., Thuery, A., Brueggen, J., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.478 · Cited by 150
Byron, S. A., Chen, H., Wortmann, A., Loch, D., Gartside, M. G., Dehkhoda, F., Blais, S. P., Neubert, T. A., Mohammadi, M., & Pollock, P. M. (2013) · Neoplasia · doi:10.1593/neo.121106 · Cited by 138 · cited 2×
“Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) 1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Cholangiocarcinoma 7 (17) 17 (39) 24 (28) Intrahepatic 6 (14) 16 (36) 22 (26) Extrahepatic 1 (2) 1 (2) 2 (2) Breast 7 (17) 5 (11) 12 (14) Colorectal 7 (17) 5 (11) 12 (14)…”
Kalyukina, M., Yosaatmadja, Y., Middleditch, M., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019) · ChemMedChem · doi:10.1002/cmdc.201800719 · Cited by 133
Voss, M. H., Hierro, C., Heist, R. S., Cleary, J. M., Meric‐Bernstam, F., Tabernero, J. M., Jankú, F., Gandhi, L., Iafrate, A. J., Borger, D. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1959 · Cited by 124 · cited 3×
“Other 1 (2) 1 (2) 2 (2) Missing/unknown 9 (21) 11 (25) 20 (23) ECOG PS, n (%) 0 10 (24) 16 (36) 26 (30) 1 32 (76) 28 (64) 60 (70) Cancer type, n (%) Cholangiocarcinoma 7 (17) 17 (39) 24 (28) Intrahepatic 6 (14) 16 (36) 22 (26) Extrahepatic 1 (2) 1 (2) 2 (2) Breast 7 (17) 5 (11) 12 (14) Colorectal 7 (17) 5 (11) 12 (14)…”
Self-citation
Cited by
Gastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
Self-citationFutibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206834 · Cited by 613
Self-citationNakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 298
Meric-Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J., Arkenau, H.-T., Tran, B., Kelley, R. K., Park, J. O., Javle, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0697 · Cited by 258
Self-citationWu, Q., Zhen, Y., Shi, L., Vu, P., Greninger, P., Adil, R., Merritt, J., Egan, R., Wu, M.-J., Yin, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1168 · Cited by 104
Self-citation
Metadata
- Authors
- Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K. A., Matos, I., & Arkenau, H.-T.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 31
- Issue
- 10
- Pages
- 1405-1412
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3039776795
- Cited by
- 159
- References
- 13
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.